Inflammation Markers in Multiple Sclerosis: CXCL16 Reflects and May Also Predict Disease Activity

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Holmøy, Trygve ^a,b   Løken Amsrud, Kristin Ingeleiv ^b,c   Bakke, Søren Jacob ^d   Beiske, Antonie G ^e   Bjerve, Kristian S ^f   Hovdal, Harald ^f   Lilleås, Finn ^g   Midgard, Rune ^h,i   Pedersen, Tom ^j   Šaltyte Benth, Jutrate ^a,b   Torkildsen, Øivind ^k,l   Wergeland, Stig ^k,l   Myhr, Kjell Morten ^k,l   Michelsen, Annika E ^m   Aukrust, Pål ^b,m   Ueland, Thor ^b,m  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c INNLANDET HOSPITAL TRUST   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e Multiple Sclerosis Centre Hakadal   (Norway)

^f TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^g Curato Oslo   (Norway)

^h Molde Hospital   (Norway)

ⁱ NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^j Unilabs   (France)

^k HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^l UNIVERSITY OF BERGEN   (Norway)

^m OSLO UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CXCL16 CHEMOKINE; DOCOSAHEXAENOIC ACID; GELATINASE B; ICOSAPENTAENOIC ACID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; OMEGA 3 FATTY ACID; OSTEOPONTIN; OSTEOPROTEGERIN; PENTRAXIN 3; PLACEBO; SECONDARY LYMPHOID TISSUE CHEMOKINE; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TYPE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL INTERACTION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; DRUG EFFECT; ENZYME BLOOD LEVEL; EXTRACELLULAR MATRIX; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BIOLOGICAL MARKERS; CHEMOKINES, CXC; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; ODDS RATIO; PROGNOSIS; RECEPTORS, SCAVENGER;

EID: 84884391008     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075021     Document Type: Article

References (38)

1. Graber JJ, Dhib-Jalbut S, (2011) Biomarkers of disease activity in multiple sclerosis. J Neurol Sci 305: 1-10. doi:10.1016/j.jns.2011.03.026. PubMed: 21463872.
2. Romi F, Helgeland G, Gilhus NE, (2012) Serum levels of matrix metalloproteinases: implications in clinical neurology. Eur Neurol 67: 121-128. doi:10.1159/000334862. PubMed: 22262194.
3. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, et al. (1999) Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 5: 49-55. doi:10.1038/4734. PubMed: 9883839.
4. Kyritsis N, Kizil C, Zocher S, Kroehne V, Kaslin J, et al. (2012) Acute inflammation initiates the regenerative response in the adult zebrafish brain. Science 338: 1353-1356. doi:10.1126/science.1228773. PubMed: 23138980.
5. Schwarz S, Knorr C, Geiger H, Flachenecker P, (2008) Complementary and alternative medicine for multiple sclerosis. Mult Scler 14: 1113-1119. doi:10.1177/1352458508092808. PubMed: 18632773.
6. Zhang W, Li P, Hu X, Zhang F, Chen J, et al. (2011) Omega-3 polyunsaturated fatty acids in the brain: metabolism and neuroprotection. Front Biosci 16: 2653-2670. doi:10.2741/3878. PubMed: 21622201.
7. Calder PC, (2012) Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology? Br J Clin Pharmacol 75: 645-662.
8. Mehta LR, Dworkin RH, Schwid SR, (2009) Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis. Nat Clin Pract Neurol 5: 82-92. doi:10.1038/ncpneuro1009. PubMed: 19194388.
9. Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, et al. (2012) omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol 69: 1044-1051. archneurol.2012.283 doi:10.1001/archneurol.2012.283. PubMed: 22507886.
10. Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, et al. (2001) Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 115: 192-198. doi:10.1016/S0165-5728(01)00261-2. PubMed: 11282170.
11. Sellebjerg F, Börnsen L, Khademi M, Krakauer M, Olsson T, et al. (2009) Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 73: 2003-2010. doi:10.1212/WNL.0b013e3181c5b457. PubMed: 19996075.
12. Krumbholz M, Theil D, Steinmeyer F, Cepok S, Hemmer B, et al. (2007) CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. J Neuroimmunol 190: 72-79. doi:10.1016/j.jneuroim.2007.07.024. PubMed: 17825430.
13. Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisäkk P, et al. (2006) CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 129: 200-211. doi:10.1093/brain/awh680. PubMed: 16280350.
14. Abel S, Hundhausen C, Mentlein R, Schulte A, Berkhout TA, et al. (2004) The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 172: 6362-6372. PubMed: 15128827.
15. Rosito M, Deflorio C, Limatola C, Trettel F, (2012) CXCL16 orchestrates adenosine A3 receptor and MCP-1/CCL2 activity to protect neurons from excitotoxic cell death in the CNS. J Neurosci 32: 3154-3163. 32/9/3154 doi:10.1523/JNEUROSCI.4046-11.2012. PubMed: 22378888.
16. Fukumoto N, Shimaoka T, Fujimura H, Sakoda S, Tanaka M, et al. (2004) Critical roles of CXC chemokine ligand 16/scavenger receptor that binds phosphatidylserine and oxidized lipoprotein in the pathogenesis of both acute and adoptive transfer experimental autoimmune encephalomyelitis. J Immunol 173: 1620-1627. PubMed: 15265890.
17. O'Connor RA, Li X, Blumerman S, Anderton SM, Noelle RJ, et al. (2012) Adjuvant immunotherapy of experimental autoimmune encephalomyelitis: immature myeloid cells expressing CXCL10 and CXCL16 attract CXCR3+CXCR6+ and myelin-specific T cells to the draining lymph nodes rather than the central nervous system. J Immunol 188: 2093-2101. jimmunol.1101118 doi:10.4049/jimmunol.1101118. PubMed: 22287719.
18. le Blanc LM, van Lieshout AW, Adema GJ, van Riel PL, Verbeek MM, et al. (2006) CXCL16 is elevated in the cerebrospinal fluid versus serum and in inflammatory conditions with suspected and proved central nervous system involvement. Neurosci Lett 397: 145-148. doi:10.1016/j.neulet.2005.12.029. PubMed: 16406320.
19. Hendrickx DA, Koning N, Schuurman KG, van Strien ME, van Eden CG, et al. (2013) Selective upregulation of scavenger receptors in and around demyelinating areas in multiple sclerosis. J Neuropathol Exp Neurol 72: 106-118. doi:10.1097/NEN.0b013e31827fd9e8. PubMed: 23334594.
20. Selmaj K, Papierz W, Glabiński A, Kohno T, (1995) Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol 56: 135-141. doi:10.1016/0165-5728(94)00139-F. PubMed: 7860709.
21. Voltz R, Hartmann M, Spuler S, Scheller A, Mai N, et al. (1997) Multiple sclerosis: longitudinal measurement of interleukin-1 receptor antagonist. J Neurol Neurosurg, Psychiatry 62: 200-201. doi:10.1136/jnnp.62.2.200-b. PubMed: 9048730.
22. Kurban S, Akpinar Z, Mehmetoglu I, (2008) Receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin levels in multiple sclerosis. Mult Scler 14: 431-432. doi:10.1177/1352458507084028. PubMed: 18208894.
23. Hofbauer LC, Cepok S, Hemmer B, (2004) Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. Acta Neuropathol 107: 575-577. doi:10.1007/s00401-004-0854-y. PubMed: 15106011.
24. Hartung HP, Reiners K, Archelos JJ, Michels M, Seeldrayers P, et al. (1995) Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 38: 186-193. doi:10.1002/ana.410380210. PubMed: 7544573.
25. Rieckmann P, Martin S, Weichselbraun I, Albrecht M, Kitze B, et al. (1994) Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology 44: 2367-2372. doi:10.1212/WNL.44.12.2367. PubMed: 7527508.
26. Bilińska M, Frydecka I, Podemski R, Gruszka E, (2002) Serum levels of sTNFR-1 and sFas in patients with relapsing-remitting multiple sclerosis. Med Sci Monit 8CR720-3. PubMed: 12388926.
27. Waubant E, (2006) Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis Markers 22: 235-244. doi:10.1155/2006/709869. PubMed: 17124345.
28. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, et al. (1999) Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 53: 1397-1401. doi:10.1212/WNL.53.7.1397. PubMed: 10534241.
29. Fainardi E, Castellazzi M, Bellini T, Manfrinato MC, Baldi E, et al. (2006) Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult Scler 12: 294-301. doi:10.1191/135248506ms1274oa. PubMed: 16764342.
30. Mirshafiey A, Mohsenzadegan M, (2009) TGF-beta as a promising option in the treatment of multiple sclerosis. Neuropharmacology 56: 929-936. doi:10.1016/j.neuropharm.2009.02.007. PubMed: 19285095.
31. Huss DJ, Winger RC, Cox GM, Guerau-de-Arellano M, Yang Y, et al. (2011) TGF-beta signaling via Smad4 drives IL-10 production in effector Th1 cells and reduces T-cell trafficking in EAE. Eur J Immunol 41: 2987-2996. doi:10.1002/eji.201141666. PubMed: 21728174.
32. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, et al. (2006) Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441: 231-234. doi:10.1038/nature04754. PubMed: 16648837.
33. Luo J, Ho PP, Buckwalter MS, Hsu T, Lee LY, et al. (2007) Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. J Clin Invest 117: 3306-3315. doi:10.1172/JCI31763. PubMed: 17965773.
34. Wang H, Wang K, Wang C, Zhong X, Qiu W, et al. (2013) Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica. Mult Scler 19: 926-931. doi:10.1177/1352458512457845. PubMed: 23012252.
35. Gallai V, Sarchielli P, Trequattrini A, Franceschini M, Floridi A, et al. (1995) Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. J Neuroimmunol 56: 143-153. doi:10.1016/0165-5728(94)00140-J. PubMed: 7860710.
36. Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, et al. (2005) Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids 73: 397-404. doi:10.1016/j.plefa.2005.05.024. PubMed: 16099630.
37. Shinto L, Marracci G, Baldauf-Wagner S, Strehlow A, Yadav V, Stuber L, et al. (2009) Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis. Prostaglandins Leukot Essent Fatty Acids 80: 131-136. doi:10.1016/j.plefa.2008.12.001. PubMed: 19171471.
38. Johnson GH, Fritsche K, (2012) Effect of dietary linoleic acid on markers of inflammation in healthy persons: a systematic review of randomized controlled trials. J Acad Nutr Diet 112: 1029-1041. PubMed: 22889633.